Table 1 Patient characteristics stratified by functional outcome at 90 days
Variables | Overall | Good functional outcome | Poor functional outcome | P value |
|---|---|---|---|---|
(n = 432) | (n = 169) | (n = 263) | ||
Age, years, mean (SD) | 69.2 (13.5) | 64.9 (13.9) | 72.0 (12.5) | < 0.001 |
Male, n (%) | 236 (54.6) | 109 (64.4) | 127 (48.3) | < 0.001 |
Hypertension, n (%) | 259 (60.0) | 95 (56.2) | 164 (62.4) | 0.203 |
Diabetes, n (%) | 99 (22.9) | 34 (20.1) | 65 (24.7) | 0.267 |
hyperlipemia, n (%) | 34 (7.9) | 13 (7.7) | 21 (8.0) | 0.912 |
Atrial fibrillation, n (%) | 216 (50.0) | 63 (37.3) | 133 (58.2) | < 0.001 |
Valvular heart diseases, n (%) | 74 (17.1) | 25 (14.8) | 49 (18.6) | 0.301 |
Coronary heart diseases, n (%) | 63 (14.6) | 22 (13.0) | 41 (15.6) | 0.460 |
Previous stroke, n (%) | 39 (9.0) | 12(7.1) | 27 (10.3) | 0.263 |
Current smoking, n (%) | 107 (24.8) | 52 (30.8) | 55 (20.9) | 0.021 |
Alcohol consumption, n (%) | 100 (23.1) | 52 (30.8) | 51 (19.4) | 0.021 |
Statin use before admission, n (%) | 39 (9.0) | 14 (8.3) | 25 (9.5) | 0.665 |
Baseline NIHSS, median (Q1-Q3) | 14 (9–18) | 9 (6–14) | 15(12–20) | < 0.001 |
LDL-C, mmol/L, mean (SD) | 2.55 (0.93) | 2.59 (0.91) | 2.53 (0.95) | 0.496 |
HDL, mmol/L, mean (SD) | 1.27 (0.42) | 1.25 (0. 49) | 1.29 (0.36) | 0.332 |
TG, mmol/L, median (Q1-Q3) | 1.24 (0.87–1.89) | 1.20 (0.85–1.94) | 1.20 (0.88–1.81) | 0.566 |
TC, mmol/L, mean (SD) | 4.23 (1.13) | 4.22 (1.13) | 4.23 (1.13) | 0.966 |
Serum glucose, mmol/L, mean (SD) | 7.53 (6.49–9.18) | 7.96 (2.76) | 8.57 (3.04) | 0.035 |
White blood cell, a10^9 /L, mean (SD) | 8.47 (3.19) | 8.23 (2.77) | 8.62 (3.43) | 0.207 |
TOAST classification, n (%) |  |  |  | < 0.001 |
 Large-artery Atherosclerosis | 139 (32.2) | 59 (34.9) | 80 (30.4) |  |
 Cardio-embolism | 192(44.4) | 57 (33.7) | 135 (51.3) |  |
 Lacunar | 28 (6.5) | 22 (13.0) | 6 (2.3) |  |
 Other | 13 (3.0) | 7 (4.1) | 6 (2.3) |  |
 Undetermined | 60 (13.9) | 24 (14.2) | 36 (13.7) |  |
Reperfusion therapy method, n (%) | Â | Â | Â | 0.092 |
 thrombolysis only | 124 (28.7) | 58 (34.3) | 66 (25.1) |  |
 thrombectomy only | 210 (48.6) | 70 (41.4) | 140 (53.2) |  |
 thrombolysis and thrombectomy | 98 (22.7) | 41 (24.3) | 57 (21.7) |  |
Statin use during hospitalization, n (%) | 263 (60.9) | 103 (60.9) | 160 (60.8) | 0.982 |
Interval between stroke onset and emergency department, h, median (Q1-Q3) | 2.5 (1.8-3.0) | 2.3 (2.0–3.0) | 2.5 (1.7–3.5) | 0.610 |
Interval between stroke onset and admission measurement of LDL-C, h, median (Q1-Q3) | 3.1 (2.2–3.9) | 3.1 (2.1–3.8) | 3.1 (2.1–3.8) | 0.685 |
Interval between admission and follow-up measurement of LDL-C, d, median (Q1-Q3) | 3.1 (0.8–6.6) | 1.7 (0.6–6.4) | 3.4 (1.0-7.1) | 0.008 |
aΔLDL-C, mmol/L, median (Q1-Q3) | 0.43 (0.08–0.94) | 0.28 (0.07–0.78) | 0.52 (0.10–1.03) | 0.009 |
The lowest LDL-C during hospitalization, mmol/l, median (Q1-Q3) | 1.92 (1.38–2.44) | 2.11 (1.48–2.69) | 1.83 (1.34–2.32) | 0.002 |
LDL-C variation, n (%) | Â | Â | Â | 0.542 |
decreased (ΔLDL-C > 0) | 357 (82.6) | 142 (84.0) | 215 (81.7) |  |
increased (ΔLDL-C ≤ 0) | 75 (17.4) | 27 (16.0) | 48 (18.3) |  |